Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-801 Smallpox and Monkeypox Vaccine and Recombinant Pox Virus (RPV) Platform Technology
June 01, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Strengthens Patent Portfolio Protecting Horsepox-Based Live Virus Vaccines TNX-1840 and TNX-1850 are Potential RPV Vaccines Designed to Protect Against COVID-19 Confirms Leadership Position in...
Tonix Pharmaceuticals Announces Share Repurchase Program
May 31, 2022 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that its Board...
Tonix Pharmaceuticals Announces Two Oral Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) on Prevention of Rejection in Kidney and Heart Allograft Transplantation at the 2022 American Transplant Congress
May 31, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced two upcoming oral...
Tonix Pharmaceuticals Extends Research Collaboration with the University of Alberta to Develop Antiviral Drugs Against SARS-CoV-2
May 18, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into...
Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split
May 16, 2022 13:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it will...
Tonix Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
May 09, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Fibromyalgia Phase 3 Trial of TNX-102 SL Enrollment Initiated; Results from Interim Analysis Expected First Quarter 2023 Long COVID IND Cleared for TNX-102 SL; Phase 2 Trial Expected to Initiate...
Tonix Pharmaceuticals to Present at the 2022 Q2 Investor Summit
April 28, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating...
Tonix Pharmaceuticals to Present at B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
April 25, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., April 25, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, President and...
Tonix Pharmaceuticals Announces Results of Retrospective Observational Database Study In Over 50,000 Long COVID Patients
April 20, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Over 40% of Long COVID Patients Had Fibromyalgia-Like Multi-Site Pain Symptoms Rate of Opioid Use in Long COVID Patients with Multi-Site Pain is a Potential Health Concern CHATHAM, N.J., April 20,...
Tonix Pharmaceuticals to Participate in the NobleCon18 Investor Conference
April 12, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, President and...